Last reviewed · How we verify
Afinitor
At a glance
| Generic name | Afinitor |
|---|---|
| Also known as | Everolimus |
| Sponsor | Central European Society for Anticancer Drug Research |
| Target | Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Angiomyolipoma of kidney
- Carcinoma of breast
- Hormone receptor positive malignant neoplasm of breast
- Pancreatic Neuroendocrine Tumor
- Prevention of Kidney Transplant Rejection
- Renal cell carcinoma
- Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis
- Tuberous sclerosis syndrome
Common side effects
- Stomatitis
- Infections
- Rash
- Fatigue
- Diarrhea
- Decreased appetite
- Nausea
- Abdominal pain
- Edema
- Fever
- Headache
- Hyperglycemia
Serious adverse events
- Fatal adverse reactions
- Pneumonitis
- Dyspnea
- Stomatitis (Grade 3-4)
- Diarrhea (Grade 3-4)
- Infections (Grade 3-4)
- Hyperglycemia (Grade 3-4)
- Fatigue (Grade 3-4)
- Anemia (Grade 3-4)
- Thrombocytopenia (Grade 3-4)
Key clinical trials
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (PHASE2)
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (PHASE2, PHASE3)
- Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (PHASE2)
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant (PHASE2)
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (PHASE2)
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) (PHASE1)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afinitor CI brief — competitive landscape report
- Afinitor updates RSS · CI watch RSS
- Central European Society for Anticancer Drug Research portfolio CI